Streetbeat News

Products Services

SWI

SolarWinds announced an enhancement to its Database Performance Analyzer, introducing advanced support for PostgreSQL. This update aims to provide deeper insights and improved performance monitoring for databases utilizing PostgreSQL, reflecting SolarWinds' commitment to expanding its product capabilities and addressing the needs of its diverse customer base.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:31 am

PTCT

PTC Therapeutics announced that the FDA has accepted and granted priority review to its Biologics License Application (BLA) for Upstaza, a potential treatment for a specific medical condition. This marks a significant milestone for the company, potentially accelerating the approval process.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:31 am

AON

Binary Defense, a Managed Detection and Response (MDR) provider, has announced a collaboration with Aon, a global professional services firm, to become Aon's exclusive MDR provider for small and medium-sized enterprises. The financial terms of the collaboration were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:10 am

VERI

Veritone has announced a strategic partnership with Creative Artists Agency for the launch of theCAAvault, a new initiative aimed at leveraging Veritone's artificial intelligence technology. This collaboration is expected to enhance content creation and management for Creative Artists Agency's diverse client base.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:10 am

CSTL

Castle Biosciences has announced the expansion of evidence supporting the performance of its TissueCypher Barrett's Esophagus Test, which is designed to predict the future development of esophageal cancer. This development could potentially enhance the company's product portfolio and market position by providing a valuable tool for early detection and management of esophageal cancer risk.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:07 am

LYRA

A new post-hoc analysis of pooled Phase 3 data reveals that INPEFA (Sotagliflozin) significantly reduces the risk of heart failure events in patients with preserved ejection fraction. This finding could have substantial implications for the treatment of heart failure, potentially positioning INPEFA as a leading therapeutic option in this patient population. The analysis, which draws on data from several Phase 3 trials, underscores the drug's efficacy in a condition that has historically been challenging to manage.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:04 am

GXO

GXO Logistics has implemented a groundbreaking large-scale robotics solution in France, marking a significant advancement in their operational capabilities.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:02 am

BITF

Bitfarms has announced the doubling of its Yguazu power capacity to 200 MW by adding an additional 100 MW of hydropower in Paraguay. This expansion is aimed at enhancing the company's cryptocurrency mining operations by leveraging renewable energy sources.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:01 am

STLA

Stellantis shares are trading higher following President Biden's announcement of tariffs on Chinese electric vehicles (EVs). Additionally, Stellantis and Leapmotor are set to begin sales of budget EVs in nine European countries.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:47 am

SE

Sea Limited (SE) has reaffirmed its FY24 outlook, with Shopee expecting GMV growth in the high teens range and adjusted EBITDA to turn positive in the second half of the year. Garena, led by Free Fire's strong performance, is back to positive growth. Free Fire continues to attract new users in its 7th year, and Sea Limited is confident in its roadmap for profitable growth.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:42 am